How scarcity of niche biotech ingredients has slowed Covid-19 vaccine production
Submitted by mike kraft on
Submitted by mike kraft on
Submitted by mike kraft on
RICHMOND, Va. — When tiny glass vials of coronavirus vaccine began rolling off production lines late last year, federal health officials set aside a big stash for nursing homes being ravaged by the virus. Health providers around the country figured as well that it was prudent to squirrel away vials to ensure that everyone who got a first dose of vaccine got a second one.
Two months later, it is clear both strategies went overboard.
Submitted by mike kraft on
Submitted by mike kraft on
Submitted by mike kraft on
Submitted by mike kraft on
Submitted by mike kraft on
One year into the COVID-19 pandemic, many millions of N95 masks are pouring out of American factories and heading into storage. Yet doctors and nurses like Turner say there still aren’t nearly enough in the “ICU rooms with high-flow oxygen and COVID germs all over.”
Submitted by mike kraft on
Submitted by mike kraft on
Submitted by mike kraft on
(Reuters) - When the U.S. government began shipping COVID-19 vaccines in December, state health providers could not administer shots fast enough to keep pace with deliveries and millions of doses sat waiting for arms.